Abstract Circulating tumor cell (CTC) count has been shown to be an independent predictor of progression in metastatic breast, prostate, and colorectal cancer. A cutpoint is generally used to identify favorable and unfavorable response groups. In this study, we propose an approach in which the number of CTCs is analyzed as a continuous predictor, to detect the shape of the relationship between CTCs and prognosis of metastatic breast cancer. We evaluated the association of baseline CTC with progression-free survival (PFS) and overall survival (OS) in a series of 80 patients treated for advanced breast cancer at the European Institute of Oncology, Milan. The association between CTCs and prognosis was analyzed with standard categorical survival analysis and spline regression models. At baseline, median age was 55 years; 33 patients were newly diagnosed with metastatic breast cancer (41%), while 28 (35%) and 19 (24%) were pretreated with one and two previous chemotherapy lines, respectively. After a median follow-up of 28 months, 76 disease progressions and 44 deaths were observed. Kaplan-Meier curves showed a clear association between CTCs and PFS (P-value 0.03) and OS (Pvalue \ 0.01). Patients with no CTC at baseline had a significantly better prognosis. When analyzing the CTCs as a continuous variable, we found an increase in risk with increasing number of CTCs, for both PFS and OS. The increase rate lessened after approximately 5 CTCs. CTCs represent a robust prognostic factor in the metastatic breast cancer setting. A nonlinear increase in risk of both progression and death with increasing number of CTCs was observed, with a lessening increase after approximately 5 CTCs. If distinct prognostic groups are to be identified, women with no CTC could plausibly represent a distinct favorable one.
Introduction
Despite the essential contributions of screening programs in early detection of breast cancer and the continuous advances in treatment, 6-10% of women diagnosed with breast cancer present with metastatic disease [1] , and others develop metastatic disease in the course of time, with a probability depending on tumor stage, biology, and treatments used. The 5-year overall survival (OS) rate among such patients rarely exceeds 20% [2] . Since no specific predictive factors for treatment response have been satisfactorily validated for use in a standard clinical setting, patients are usually treated with a set of agents until progression becomes evident.
Circulating tumor cells (CTCs) have been shown to be an independent prognostic factor in metastatic breast cancer (MBC) [3] [4] [5] [6] , in metastatic prostate cancer [7] [8] [9] [10] and in metastatic colorectal cancer [11, 12] . They represent a promising tool for therapeutic monitoring: an elevated number of CTCs measured at any time in the clinical course were associated with a high likelihood of a very short time to progression.
When studying the link between CTC count and evolution of disease, researchers generally use cut-off values to identify favorable and unfavorable response groups. For example, in studies on MBC, a cutpoint of 5 CTCs has been generally adopted [3, 4, 13, 14] . Dichotomization has some perceived advantages, such as simplicity, easy interpretation of the results, and functionality in clinical practice, but also some intrinsic problems, such as loss of information and statistical power, increased probability of false positive results, and impossibility of detecting nonlinear relationships between the predictor and the outcome [15] [16] [17] [18] .
In this study, we will propose an approach in which the number of CTCs is analyzed as a continuous predictor, to detect the shape of the relationship between CTCs and prognosis of MBC patients.
Patients and methods
Details of study design are described elsewhere [4] . In brief, this was a prospective mono-institutional study conducted at the European Institute of Oncology in Milan aimed to evaluate the prognostic significance of CTCs, detection in patients with advanced breast cancer. In particular, the study investigated the association between the number of CTCs at baseline and patients' characteristics, as well as their modification during treatments, in women with histological diagnosis of breast cancer and evidence of metastatic disease, starting a new line of therapy and/or in those in patients already treated for the advanced disease with a maximum of two previous lines of chemotherapy. A baseline blood draw for enumeration of CTCs was performed; subsequently, blood samples were collected after 4 and 8 weeks, at the time of the first clinical evaluation, and every 2 months thereafter-until disease progression was documented. However, only baseline values are used in this analysis. In order to isolate and enumerate the CTCs, the CellSearch TM System (Veridex) was used. It consists of two instruments: (1) the CellTracks AutoPrep System for the isolation and staining of the cells, and (2) CellSpotter Analyzer, for the analysis and enumeration of the CTCs.
Results are expressed as the number of tumor cells/7.5 ml of blood. The conventional threshold of 5 CTCs/7.5 ml was used for the PFS and OS analysis at each of the blood draw time points. We additionally used 20 CTCs/7.5 ml as the second arbitrary cut-off point because it was a round number that guaranteed similar number of patients in all strata.
Statistical methods
Progression-Free Survival (PFS) and OS were defined as the length of time from the baseline blood draw to disease progression and death from breast cancer, respectively. PFS and OS were estimated using the Kaplan-Meier method. In the absence of events, PFS and OS were censored at the last follow-up visit. The log-rank test was used to test differences in PFS and OS between subgroup of patients, according to CTC count distribution. The following four categories were considered: 0, 1-4, 5-20, and [20. In order to investigate the shape of the relationship between CTC and the hazard of progression, multivariable Cox proportional hazard models were fitted. CTC count was firstly modeled as a categorical variable. Then, restricted cubic spline models were used. Cubic splines are smoothly joined piecewise third-order polynomials [19] . Polynomials are fitted within intervals delimited by knots, and restrictions are placed on the resulting curve to ensure a smooth appearance at the knot points. Three knots were set at the 25th, 50th, and 75th percentile of the CTC distribution, corresponding to 1, 5, and 20 CTCs, respectively. Results were presented in terms of Hazard Ratio (HR), using 0 CTC as reference. Owing to the skewness of the distribution of CTCs, the log-transformed data were used in the analyses and reported on the log scale in the figures. Since the CTC count could be zero, the log(CTC ? 1) transformation was used.
All analyses were carried out with the SAS software (SAS Institute, Cary, NC) and the R (http://cran.r-project. org/) software with the Harrell's Design and Hmisc libraries. All the reported P-values were two sided. Table 1 . Thirty-three patients were newly diagnosed with MBC (41%), while 28 (35%) and 19 (24%) were pretreated with one and two previous chemotherapy lines, respectively. Regarding the final treatment, nine patients received only hormone therapy, 43 patients chemotherapy and 28 patients chemotherapy combined with HER2/Neu directed treatments. Patients who presented with both bone and visceral metastases had a statistically significant higher number of CTCs compared to other patients (P \ 0.01). The associations between number of metastatic sites and number of CTCs and between Ca 15-3 and number of CTCs were borderline statistically significant (P = 0.06 and P = 0.08, respectively). With regard to the characteristics of the primary tumor, number of positive lymph nodes was positively associated with the number of CTCs (P = 0.03) and Her2/Neu patients had lower CTC values (P = 0.01).
Univariate survival analysis is reported in Table 2 . After a median follow-up of 28 months (range 1-45), we observed 76 progressions and 44 deaths, all due to breast cancer. Median survival was 33 months from baseline. Number of CTCs at baseline, categorized as 0, 1-4, 5-20, and [20, resulted significantly associated with PFS (P = 0.03) and OS (P \ 0.01). The corresponding Kaplan-Meier curves are shown in Fig. 1a , c, respectively. The 12 women with no CTC showed a longer median progression-free and overall median survival compared to women with C1 CTC (P = 0.07 and P \ 0.01, respectively). When comparing 0 CTC to 1-4 CTCs, we found a borderline statistically significant difference for OS (P = 0.08), but not for PFS (P = 0.61). Stage of primary tumor was associated with OS, even if no interpretable trend emerged. Number of positive lymph nodes, Her2/neu, Ca 15-3, number of metastatic sites at baseline and type of metastatic sites resulted significantly associated with PFS and/or OS and were included in the multivariable survival models. In Fig. 1 , besides the standard Kaplan-Meier curves, the continuous relationship between CTCs and survival is represented, together with standard multivariable HRs from Cox regression models (Fig. 1b, d ). With regard to PFS, we observed an increasing risk of progression with increasing number of CTCs. The increase rate lessened after 
Discussion
In the first report on this series of women, with nine deaths (11%) and a median follow-up of 8 months, we showed that the number of CTCs at baseline and changes in CTC's number at different follow-up points represent a strong independent predictor of PFS, but we could not show a prognostic value of CTCs on OS [4] . This study, with 44 deaths (55%) and a median follow-up of 26 months, reinforces the observations on PFS and showed a strong predictive value of CTCs also on OS. Assessment of CTC using CellSearch has been cleared by the Food and Drug Administration as a prognostic indicator, in conjunction with other clinical methods, for patients with metastatic breast, prostate, and colorectal cancers. Studies in metastatic breast, colorectal, and prostate cancer showed that patients about to start new lines of chemotherapy could be divided into groups with favourable and unfavourable prognosis on the basis of the number of CTCs measured with the analytically valid CellSearch system(Veridex, Raritan, NJ, USA) [3, [5] [6] [7] [8] [9] [10] [11] [12] [13] 20] . When studying the association between the number of CTCs and evolution of the disease, researchers generally use a single cutpoint to identify favorable and unfavorable response groups, such as 5 CTCs for MBC [3, 4, 14] , three for metastatic colorectal cancer [11] , and five for castration resistant prostate cancer [7] . Dichotomization is very common in clinical studies, since it satisfies the general need in clinical practice to label individuals as having or not having a characteristic and to decide the treatment strategy. However, converting all patients into two categories has some intrinsic problems, such as loss of information and statistical power, increased probability of false positive results, and impossibility of detecting the shape of the relationship [15] [16] [17] [18] . In addition, in the absence of a priori information, ''optimal'' cutpoints are usually obtained by trying many thresholds and choosing the one which, to some extent, gives the most satisfactory result, for example, choosing the value which minimizes the P-value of the Log-rank test [13] . The disadvantages of this approach, related to multiple testing and generalizability of the results, have been abundantly discussed in the literature [15, 16, [21] [22] [23] . Alternative strategies to dichotomization, in which continuous predictors are kept continuous and trends are investigated, have been proposed: among these, the most commonly used are fractional polynomials and spline regression models [23] [24] [25] [26] [27] [28] . When using the restricted cubic spline regression method [24, 25] , we observed a significant nonlinear increase in risk of both progression and death with increasing number of CTCs; this increase rate lessened after approximately 5 CTCs. Moreover, for OS, the increase rate became negligible after approximately 15-20 CTCs. Similar trends were found in previous reports [13, 29] . No exhaustive biological explanation has been proposed so far to explain why this plateau was reached. We think that this phenomenon might be explained through investigation of the underlying nonlinear dynamics [30, 31] of the population of CTCs, and we will focus on this point in further studies.
If researchers are not familiar with curve-fitting models, such as spline regression, then we recommend using two or three cutpoints rather than just one, to categorize individuals in more homogeneous response groups and to observe possible trends. With a categorical analysis, using 1, 5, and 20 as arbitrary cutpoints, we found that the group of women with no CTC detected could plausibly represent a distinct favorable prognostic group, showing a longer median progression-free and overall median survival compared to the other groups. Obviously, a detection of 0 CTC does not imply that there are no CTCs in circulation. For example, as reported by Tibbe et al. [29] , when 500 CTCs are in circulation, using the CellSearch TM System and assuming a blood volume of 5 l, the estimated probability of collecting 0 CTC in a 7.5 ml aliquot is 50%, and the estimated probability of detecting 0 CTC is even greater, mainly depending on the ability of the operator. False negative probabilities decrease with increasing number of CTCs in circulation and/or with increasing number of blood samples.
In conclusion, CTCs represent a robust predictive factor in the MBC setting. A nonlinear increase in risk of both progression and death with increasing number of CTCs was observed, with a lessening increase after approximately 5 CTCs.
